Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksCONCORDBIO
resources
CONCORDBIO
1,344.80+6.4 (+0.48%)
17 Jul, 12:00 AM

Annual Reports and Financial Documents

Concord Biotech Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Concord Biotech Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  • Newspaper Publication8 Jul 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting information
  • Record Date7 Jul 2026
    Intimation Of Record Date And Book Closure Date
    The register of members and share transfer book of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026. Further the Company has fixed Friday, July 24, 2026 ....
  • Business Responsibility and Sustainability Reporting (BRSR)7 Jul 2026
    Business Responsibility and Sustainability Reporting (BRSR)
    Business Responsibility and Sustainability Report for financial year 2025-26
  • Reg. 34 (1) Annual Report7 Jul 2026
    Reg. 34 (1) Annual Report.
    Annual Report for the financial year 2025-26
  • AGM7 Jul 2026
    Notice Of 41St Annual General Meeting Of The Company For The Financial Year 2025-26
    The Notice of 41st Annual General Meeting of the Company of scheduled to be held on Friday, July 31, 2026 through Video Conferencing (VC) / Other Audio-visual means(OAVM) at 12:00 Noon ....
  • Newspaper Publication6 Jul 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper advertisement for Notice of 41st Annual General Meeting.
  • Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20186 Jul 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate dated July 01, 2026 issued by MUFG Intime India Private Limited ....
  • Closure of Trading Window27 Jun 2026
    Closure of Trading Window
    Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s code of conduct for Regulating, Monitoring and Reporting ....
  • General25 Jun 2026
    Completion Of Inspection By The Pharmacy And Poisons Board (PPB) From Kenya And The National Drug Authority (NDA) From Uganda At Unit-II Formulation Facility
    We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation ....
  • Acquisition20 Jun 2026
    Announcement under Regulation 30 (LODR)-Acquisition
    We are pleased to announce that the Company has entered into an agreement to Invest in M/s. FSGE Renewable Power Private Limited for installation of Wind Solar Hybrid Power Project having ....
  • Analyst / Investor Meet19 Jun 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, scheduled to be held on 24th & 25th June, 2026.
  • Analyst / Investor Meet13 Jun 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of Schedule of Analyst / Institutional Investor meeting to be held on June 17, 2026 at 10:30 AM
  • General12 Jun 2026
    Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility
    We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection ....
  • General10 Jun 2026
    Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets, 5 Mg And 10 Mg
    We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg.
  • General2 Jun 2026
    Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP, 200 Mg/Ml
    We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
  • Analyst / Investor Meet1 Jun 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
    Earning Call Recording- For the Quarter and financial year ended on March 31, 2026
  • Newspaper Publication30 May 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Extracts of newspaper publications dated May 30, 2026 of the audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.
  • Dividend29 May 2026
    Corporate Action-Board approves Dividend
    The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
  • Change in Management29 May 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    Appointment of Cost Auditors and Internal Auditors
  • Change in Management29 May 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    The Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026 appointed Mrs. Ekta Gupta as Independent Director(Additional) of the company.

Frequently Asked Questions

Where can I download the annual report of Concord Biotech Ltd.?
Annual reports of Concord Biotech Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Concord Biotech Ltd.?
Quarterly earnings results and presentations of Concord Biotech Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Concord Biotech Ltd. publish earnings call transcripts?
Earnings call transcripts of Concord Biotech Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Concord Biotech Ltd.?
Investor presentations and annual day presentations of Concord Biotech Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Concord Biotech Ltd.?
Corporate announcements and regulatory filings of Concord Biotech Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Concord Biotech Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Concord Biotech Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Concord Biotech Ltd.?
The ISIN (International Securities Identification Number) of Concord Biotech Ltd. is INE338H01029. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Concord Biotech Ltd. listed?
Concord Biotech Ltd. is listed on NSE and BSE. The NSE symbol is CONCORDBIO and the BSE code is -.
Where can I find the shareholding pattern of Concord Biotech Ltd.?
The quarterly shareholding pattern of Concord Biotech Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Concord Biotech Ltd. on Sharpely?
Share price data for Concord Biotech Ltd. is updated as of 17 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.